Literature DB >> 29745091

Upregulation of miR-191 promotes cell growth and invasion via targeting TIMP3 in prostate cancer.

Xueling Wang1, Zhimin Shi, Xiaoxia Liu, Ying Su, Weixia Li, Haiping Dong, Liwei Zhao, Manman Li, Yunxiao Wang, Xiu Jin, Zhongchao Huo.   

Abstract

PURPOSE: Prostate cancer (PCa) is the most frequently malignant neoplasm in men. MicroRNAs (miRs) have been identified to play important biological roles in a variety of tumors. Several studies showed that miR-191 was involved in the development of different cancers, but its role in prostate cancer remains unclear.
METHODS: Human PCa cell lines DU145, PC-3 and LNCAP, and benign prostate hyperplasia (BPH) and human prostate epithelial cell line RWPE-1 were used. The expression level of miR-191 in 48 paired prostate tumor and adjacent normal tissues was assessed along with the clinical patient features. Synthetic miR-191 mimics and inhibitors were used to overexpress or inhibit the miR-191 level. CCK8 and colony formation assay were used to evaluate the cell growth. The ability of cell invasion was studied by transwell assay. Dual-luciferase experiment was used to identify the target gene and western blot was performed to evaluate the protein level.
RESULTS: miR-191 was overexpressed in PCa tissue samples compared to the normal group as well in PCa-derived cell lines. Upregulation miR-191 in PC-3 cells significantly promoted while downregulation miR-191 in DU145 cells retarded the cell proliferation and invasion. Furthermore, TIMP3 were proved to be a direct target gene of miR-191 and knockdown of TIMP3 reversed the function of miR-191 downregulation.
CONCLUSION: This study demonstrated that miR-191 promoted the cell growth and invasion ability in prostate cancer through downregulating TIMP3 and might be a potential target for the biotherapy for PCa.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29745091

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  6 in total

Review 1.  Biology of Tissue Inhibitor of Metalloproteinase 3 (TIMP3), and Its Therapeutic Implications in Cardiovascular Pathology.

Authors:  Dong Fan; Zamaneh Kassiri
Journal:  Front Physiol       Date:  2020-06-16       Impact factor: 4.566

2.  Upregulation of microRNA-191 can serve as an independent prognostic marker for poor survival in prostate cancer.

Authors:  Jing-Bo Liu; Yong-Ji Yan; Jing Shi; Ya-Bing Wu; Yan-Feng Li; Lin-Feng Dai; Xue-Tao Ma
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

3.  MicroRNA related prognosis biomarkers from high throughput sequencing data of kidney renal clear cell carcinoma.

Authors:  Minjiang Huang; Ti Zhang; Zhi-Yong Yao; Chaoqung Xing; Qingyi Wu; Yuan-Wu Liu; Xiao-Liang Xing
Journal:  BMC Med Genomics       Date:  2021-03-09       Impact factor: 3.063

4.  Dysregulation of the miRNome unveils a crosstalk between obesity and prostate cancer: miR-107 asa personalized diagnostic and therapeutic tool.

Authors:  Vicente Herrero-Aguayo; Prudencio Sáez-Martínez; Juan M Jiménez-Vacas; M Trinidad Moreno-Montilla; Antonio J Montero-Hidalgo; Jesús M Pérez-Gómez; Juan L López-Canovas; Francisco Porcel-Pastrana; Julia Carrasco-Valiente; Francisco J Anglada; Enrique Gómez-Gómez; Elena M Yubero-Serrano; Alejandro Ibañez-Costa; Aura D Herrera-Martínez; André Sarmento-Cabral; Manuel D Gahete; Raúl M Luque
Journal:  Mol Ther Nucleic Acids       Date:  2022-02-12       Impact factor: 8.886

5.  The crucial choice of reference genes: identification of miR-191-5p for normalization of miRNAs expression in bone marrow mesenchymal stromal cell and HS27a/HS5 cell lines.

Authors:  É Costé; F Rouleux-Bonnin
Journal:  Sci Rep       Date:  2020-10-20       Impact factor: 4.379

6.  The prognostic and diagnostic value of tissue inhibitor of metalloproteinases gene family and potential function in gastric cancer.

Authors:  Zhao Li; Qinwen Jing; Liucheng Wu; Jiansi Chen; Mingwei Huang; Yuzhou Qin; Tingan Wang
Journal:  J Cancer       Date:  2021-05-13       Impact factor: 4.207

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.